Clinical Trial Site Selection: The 3 Steps Sponsors and CROs Follow
Clinical trial site selection is one of the most consequential decisions in the lifecycle of a clinical study. Within the pharmaceutical industry, 45% of clinical trials are completed late, and between 70% and 80% of studies fail to meet their original timelines. Delays in site selection and activation are among the leading contributors to these overruns. For sponsors and CROs, developing a rigorous, systematic approach to clinical trial site selection is not optional. It is the foundation of study success.
Why Site Selection Determines Study Outcomes
The quality of sites chosen for a study has a direct impact on the quality of data collected, adherence to study timelines, and overall project finances. Sites that are poorly matched to a protocol’s requirements create enrollment bottlenecks, regulatory complications, and data integrity risks that can jeopardize the entire study.
To address this, sponsors and CROs follow a structured process for clinical trial site selection that typically involves three stages: defining selection criteria, identifying and gathering site information, and conducting formal site evaluations.
Step 1: Define Site Requirements and Selection Criteria
The first step in clinical trial site selection is extracting key criteria directly from the study design and protocol. These criteria serve as the objective framework against which all candidate sites will be measured.
Staff qualifications are evaluated based on availability, medical specialty, credentials, regulatory compliance history, clinical research experience, and familiarity with the indication being studied. A site may have excellent facilities but lack the investigator experience required for a complex oncology or rare disease protocol.
Facilities and equipment requirements include adequate physical space, appropriate drug and device storage, security infrastructure, and the specific equipment called for in the protocol.
Site profile and timelines encompass site type (hospital, academic medical center, private clinic, non profit, or government facility), the meeting schedule of the site’s Institutional Review Board, and the site’s typical contract negotiation timeline. Sites with slow contracting processes can add weeks or months to startup.
Population profile and access involves assessing the availability and proximity of eligible participants, the local incidence of the target disease or condition, competing trials that recruit from the same patient pool, and the site’s capacity for patient outreach and recruitment.
Previous performance looks at enrollment history across comparable studies, including whether the site has met enrollment targets on time and how it has handled similar protocols in terms of complexity and regulatory requirements.
Step 2: Identify Sites and Collect Information
Once selection criteria are defined, sponsors and CROs use multiple channels to build a list of candidate sites. These include internal sponsor databases of previously used sites, CRO external site databases, site network organizations that manage groups of sites, online and offline directories, publications of recent clinical trials in the relevant indication, listings on ClinicalTrials.gov, and referrals from within the research community.
At this stage, sponsors and CROs typically distribute a feasibility questionnaire to candidate sites. This questionnaire helps confirm population availability according to the study protocol and allows sites to demonstrate their suitability before a formal visit is arranged.
Step 3: Conduct a Formal Site Evaluation
The final stage of clinical trial site selection involves Pre Study Visits or Site Selection Visits carried out by site monitors. During these visits, the study protocol is explained in detail to the principal investigator and site staff. A structured questionnaire about the site and its patient population is completed, and the monitor prepares a formal report with findings and recommendations for the sponsor’s consideration.
Once all visits are completed, the collected information is reviewed and compared across sites in an objective decision making process. Involving site administration staff responsible for contracting and budgeting at this stage is critical. Setting timeline expectations and financial parameters early leads to more efficient study startup and reduces the risk of delays once the study is underway.
If no pre defined cost per patient has been established by the sponsor, the site should provide a forecast budget covering study setup, conduct charges, closeout fees, and applicable overhead.
How FOMAT Supports Site Selection for Sponsors and CROs
FOMAT operates a network of investigator sites across the United States that are designed to meet the demands of complex clinical trial site selection criteria. Our sites are staffed by experienced investigators across multiple therapeutic areas including oncology, nephrology, ophthalmology, infectious disease, and gastroenterology. We maintain strong regulatory compliance records, established patient recruitment infrastructure, and the operational expertise to support studies from Phase I through Phase IV.
To learn more about our Phase I capabilities, Phase II and III capabilities, or our active studies, visit fomatmedical.com.
For More Information
To read the original sources, visit Applied Clinical Trials Online and Worldwide Clinical Trials